Alivus Life Sciences Approves 76% Stake Acquisition In IQGen-X Pharma For ₹9.12 Crore

Market snapshot: Alivus Life Sciences Limited has announced that its Board of Directors has approved a Share Purchase Agreement to acquire a 76% majority stake in IQGen-X Pharma Private Limited. The transaction involves purchasing 8,60,589 equity shares for an aggregate cash consideration of approximately ₹9.12 cr, subject to customary adjustments. This strategic acquisition marks Alivus's entry into advanced formulation development, expanding its capabilities beyond its core API portfolio into oral solids, sterile injectables, and ophthalmic solutions.

Data Snapshot

• Alivus Life Sciences is acquiring a 76% majority stake in IQGen-X Pharma Private Limited, representing 8,60,589 equity shares of face value ₹10 each.
• The total deal consideration is approximately ₹9.12 cr, paid in cash and subject to contract adjustments.
• IQGen-X Pharma recorded a turnover of ₹3.48 cr for the financial year ended March 31, 2026.
• Alivus reported standalone cash reserves of ₹880.2 cr as of June 30, 2026, making the acquisition easily fundable.

What's Changed

• Alivus is utilizing its high cash reserves of ₹880.2 cr as of June 30, 2026 (up from ₹782.4 cr at the end of FY26) to expand downstream formulation capabilities.
• The acquisition marks a clear shift under Nirma Group's ownership to accelerate the independent, high-margin non-GPL segment, which now commands 89% of Alivus's total revenues.

Key Takeaways

• Pivot to Formulations: Alivus moves beyond pure API synthesis to advanced formulation development (injectables, oral solids, ophthalmics).
• Disciplined Capital Allocation: At ₹9.12 cr, this acquisition represents just over 1% of Alivus's total cash balance, preserving massive organic liquidity.
• Regulated Markets Access: IQGen-X operates in high-standard jurisdictions including the US and EU, matching Alivus's premium customer profile.

SAHI Perspective

Alivus is systematically reducing its commercial dependence on its former parent entity, Glenmark Pharmaceuticals, which experienced a 52.6% YoY decline in sales during Q1 FY27 due to client inventory rationalization. By scaling its non-GPL portfolio through strategic moves like the IQGen-X acquisition, Alivus is building a structurally more profitable business model, leveraging its net debt-free balance sheet to unlock higher-value generic service pipelines.

Market Implications

The immediate financial footprint of the transaction is negligible, given IQGen-X's ₹3.48 cr turnover in FY26. However, the long-term operational synergies will accelerate Alivus's formulation development capabilities, turning it into a fully integrated API-to-formulation CDMO partner. This transition is highly margin-accretive over a multi-year horizon.

Trading Signals

Market Bias: Bullish

The board's approval of this transaction demonstrates efficient capital deployment, using a fraction of Alivus's ₹880.2 cr cash reserve to secure high-value formulation capabilities. This shift supports the high-margin non-GPL segment and accelerates the integrated CDMO strategy, backed by a strong standalone EBITDA margin of 36.6% in Q1 FY27.

Overweight: Active Pharmaceutical Ingredients (APIs), Contract Development and Manufacturing (CDMO), Biotechnology & Drugs

Trigger Factors:

• Formal transaction closure, expected by the end of calendar year 2026.
• Successful integration of IQGen-X's research pipeline into Alivus's commercial operations.
• Timing and outcome of regulatory inspections at the Solapur manufacturing facility.

Time Horizon: Medium-term (3–12 months)

Industry Context

The global generic and specialty pharmaceutical industry is seeing active consolidation as API manufacturers scale up to provide advanced formulation capabilities. Integrating custom research operations for complex formats such as sterile injectables and ophthalmics represents a key differentiator, especially ahead of a wave of global high-potency API patent expiries expected toward the end of calendar 2027.

Key Risks to Watch

• Custom research pipeline integration risks between Alivus and IQGen-X Pharma.
• Extended regulatory clearance timelines for expanded manufacturing facilities such as Solapur.
• Volatility in global raw material prices, particularly solvents and key starting materials.

Recent Developments

Alivus Life Sciences presented strong Q1 FY27 results on July 30, 2026, where standalone net profit jumped 31.8% YoY to ₹160.08 cr. Standalone revenue grew 6.4% YoY to ₹640.41 cr, fueled by a 26.5% YoY expansion in non-GPL sales, which offset a sharp inventory-led contraction in GPL segment sales.

Closing Insight

Alivus's tactical acquisition of IQGen-X Pharma showcases smart capital deployment, adding advanced formulation capabilities for a minor cash outlay of ₹9.12 cr. This helps Alivus construct a fully integrated generic services platform, positioning the debt-free company for structural, margin-led growth.

High Performance Trading with SAHI.